Equillium, Inc.EQEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe autoimmune and inflammatory diseases with high unmet medical needs. It advances pipeline candidates targeting immune system dysregulation, primarily catering to patients and healthcare providers across the United States.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. | 11.70% | 4.3M | — | 2024-11-14 |
| Takeda Pharmaceutical Company Limited | 5.20% | 1.8M | — | 2024-01-19 |
Insider Transactions
Net 90d: −$1.32M · buys $0 / sells $1.32MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-13 | Christine Zedelmayer | Sr. Vice President and COO | Option exercise | 120.3K | $0.79 | $94.4K |
| 2026-03-13 | Christine Zedelmayer | Sr. Vice President and COO | Sell (open market) | 120.3K | $2.50 | $300.8K |
| 2026-03-09 | Christine Zedelmayer | Sr. Vice President and COO | Option exercise | 35.7K | $0.79 | $28.0K |
| 2026-03-09 | Christine Zedelmayer | Sr. Vice President and COO | Option exercise | 41.7K | $0.79 | $32.7K |
| 2026-03-09 | Christine Zedelmayer | Sr. Vice President and COO | Option exercise | 75.0K | $0.79 | $58.9K |
| 2026-03-09 | Christine Zedelmayer | Sr. Vice President and COO | Sell (open market) | 181.2K | $2.00 | $362.4K |
| 2026-02-19 | Christine Zedelmayer | Sr. Vice President and COO | Option exercise | 109.4K | $0.79 | $85.9K |
| 2026-02-19 | Christine Zedelmayer | Sr. Vice President and COO | Sell (open market) | 109.4K | $1.78 | $194.8K |
| 2026-02-19 | Christine Zedelmayer | Sr. Vice President and COO | Option exercise | 76.6K | $0.73 | $55.9K |
| 2026-02-19 | Christine Zedelmayer | Sr. Vice President and COO | Sell (open market) | 76.6K | $1.74 | $133.3K |
1–10 of 14
Page 1 / 2